"Lower generic penetration in Italy, Spain, Portugal and France offers future growth potential as share of generics improves," the company said in an investor presentation.Aurobindo Pharma looks to push deeper into EU, US over next 3-4 years
"Lower generic penetration in Italy, Spain, Portugal and France offers future growth potential as share of generics improves," the company said in an investor presentation.
0 коммент.:
Отправить комментарий